Citation

Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. Eur. J. Psychotraumatol. 2016; 7: e31858.

Affiliation

Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT.

Copyright

(Copyright © 2016, The Author(s), Publisher Co-action Publishing)

DOI

unavailable

PMID

27837583

Abstract

Posttraumatic stress disorder (PTSD) is a chronic debilitating psychiatric disorder characterized by symptoms of re-experience, avoidance, and hyperarousal that can arise immediately or many years after exposure to a traumatic event and injury. Although extensive research has been done over the past 30 years, the etiology of PTSD remains largely unknown. Several neurobiological systems have been implicated in the pathophysiology and vulnerability for developing PTSD; however, first-line pharmacotherapies are limited. Less than 30% achieve full remission, and even then, approved pharmacological treatments often take weeks for therapeutic effect. This article aims to review the pathophysiology of PTSD within multiple neurobiological systems and how these mechanisms are used as pharmacologic targets of treatment, as well as their potential for future targets of intervention.

Language: en